Page 6 - Confidence Interval News Today

- Primary and secondary endpoints met with clinically meaningful and statistically significant decreases in urticaria disease activity across multiple dose...

- Primary and secondary endpoints met with clinically meaningful and statistically significant decreases in urticaria disease activity across multiple dose groups -- Sustained activity with rapid...

Approval by European Commission would expand Reblozyl’s indication to include first-line treatment of anemia in adults with MDS in Europe In the pivotal Phase 3 COMMANDS study, Reblozyl nearly...

If vorasidenib receives full approval, it would be a first-in-class target therapy to treat individuals with IDH-mutant gliomas.

/PRNewswire/ -- Servier, a global leader in oncology focused on delivering meaningful therapeutic progress for the patients it serves, today announced the FDA...

Tom Nguyen, MD, discusses a recent study he led comparing outcomes of TAVR explantation based on transcatheter heart valve type.

HCPLive is a comprehensive clinical news and information portal that provides physicians with up-to-date specialty and disease-specific resources designed to help them provide better care to patients. At HCPLive, you will find breaking news, video interviews with physician experts, in-depth conference coverage, finance and practice management updates, insight and analysis from physician contributors, and more.

Michelle Kittleson, MD, PhD, provides insight into the potential impact of a new risk score for heart transplant allocation as well as the need for more equitable cardiovascular care in the US.

A novel risk score developed by University of Chicago investigators outperformed conventional models in predicting death in heart transplant candidates, which could help bring the field closer to optimal and equitable allocation.

1. In this randomized controlled trial, the Butantan-Dengue Vaccine (Butantan-DV) was effective in the prevention of symptomatic, virologically confirmed dengue after two years, regardless of baseline serostatus. 2. Butantan-DV was effective against DENV-1 and DENV-2 serotypes across all age groups. Evidence Rating Level: 2 (Good) Study Rundown: Dengue is a mosquito-borne viral illness that can result in